Prospective Validation of a Pre-Specified Algorithm for the Management of Conduction Disturbances Following TAVR
Launched by CENTRE DE RECHERCHE DE L'INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUEBEC · Oct 23, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how to best manage a condition called conduction disturbances, which can occur after a procedure known as Transcatheter Aortic Valve Replacement (TAVR). Conduction disturbances affect the heart's electrical signals and can lead to serious complications, including the need for a permanent pacemaker. The goal of this study is to test a specific treatment plan to see if it can help reduce the need for a pacemaker while keeping patients safe from life-threatening heart issues after they leave the hospital.
To be eligible for this trial, participants should be adults aged 65 to 74 who are scheduled to have TAVR due to aortic valve disease. It's important to note that those who have had a permanent pacemaker before or who cannot commit to following the study guidelines will not be included. If you join the trial, you can expect to receive careful monitoring and treatment according to the study's plan, which aims to improve heart health outcomes after TAVR. Your participation could help doctors understand the best ways to care for patients experiencing conduction disturbances in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • -Patients with aortic valve disease undergoing transcatheter aortic valve replacement
- Exclusion Criteria:
- • Prior permanent pacemaker
- • Failure to provide signed informed consent for data collection
- • Impossibility for a follow-up
- • Unwillingness to follow the pre-specified strategy for the management of conduction disturbances
About Centre De Recherche De L'institut Universitaire De Cardiologie Et De Pneumologie De Quebec
The Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec (CRIUCQ) is a leading research institution dedicated to advancing knowledge and innovation in cardiovascular and pulmonary health. Affiliated with the Université Laval, CRIUCQ focuses on interdisciplinary clinical and translational research, aiming to improve patient outcomes through state-of-the-art methodologies and collaborative approaches. The center fosters a dynamic environment for researchers, clinicians, and healthcare professionals to explore cutting-edge treatments and interventions, contributing significantly to the global understanding of cardiopulmonary diseases. With a commitment to excellence, CRIUCQ plays a pivotal role in shaping the future of cardiovascular and respiratory medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Quebec, , Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials